Abstract
The incidence of invasive fungal infections has increased during the past 20 years in pediatric patients, with immunocompromised patients at an increased risk. Data from 2 studies that evaluated the safety and efficacy of voriconazole in pediatric patients with invasive candidiasis, esophageal candidiasis, and invasive aspergillosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
